Chimeric antigen receptor (CAR) T cell therapy is a hot topic in healthcare. Successfully used to treat certain aggressive blood cancers for about a decade now, CAR T cell therapy is capturing the growing interest of oncologists who would like to harness its power to use against other cancer types. At Frederick National Laboratory, the Biopharmaceutical Development Program—a specialized team manufacturing experimental biotherapeutics for NCI—is at the center of an effort to develop CAR T therapies that will expand cancer treatment options, particularly for pediatric malignancies.
By Frank Blanchard, Staff Writer
The U.S. Food and Drug Administration (FDA) recently approved dinutuximab (ch14.18) as an immunotherapy for neuroblastoma, a rare type of childhood cancer that offers poor prognosis for about half of the children who are affected. The National Cancer Institute’s (NCI) Biopharmaceutical Development Program (BDP) at the Frederick National Laboratory for Cancer Research produced ch14.18 for the NCI-sponsored clinical trials that proved the drug’s effectiveness against the disease.
By Ken Michaels, Staff Writer
The Biopharmaceutical Development Program (BDP) at the Frederick National Laboratory is, for the first time ever, in a single building at the Advanced Technology Research Facility (ATRF).
At Fort Detrick, BDP operations were spread out in about a dozen buildings, resulting in redundancies in maintaining various utilities (air handlers, clean steam, WFI, etc.) for multiple buildings rather than one.